钟炳娣 蔡永广

    [摘要] 分子靶向治疗是在驱动基因指导下的治疗，开启了非小细胞肺癌“个体化”与“精准”治疗时代。非小细胞肺癌驱动基因包括表皮生长因子受体(EGFR)、间变淋巴瘤激酶(ALK)和原癌基因-1(Ros-1)等。EGFR突变是非小细胞肺癌最常见的靶点，表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)是治疗EGFR突变晚期非小细胞肺癌的最有效药物，已广泛用于临床治疗，但后期耐药问题不可避免。近年来，为优化TKI治疗，EGFR-TKI联合治疗应运而生，不断探索有效的EGFR-TKI联合治疗的方案。如EGFR-TKI联合抗血管生成药物、化疗和免疫治疗等。本文就一线EGFR-TKI药物及EGFR-TKI联合治疗在一线探索的有关临床研究进展进行综述。

    [关键词] 非小细胞肺癌;表皮生长因子受体-酪氨酸激酶抑制剂;分子靶向治疗;联合治疗

    [中图分类号] R734.2? ? ? ? ? [文献标识码] A? ? ? ? ? [文章编号] 1673-9701(2020)32-0187-06

    [Abstract] Molecular targeted therapy is a treatment under the guidance of driver genes， which has opened the era of "individualization" and "precision" treatment of non-small cell lung cancer. Non-small cell lung cancer driver genes include epidermal growth factor receptor(EGFR)， anaplastic lymphoma kinase(ALK) and proto-oncogene-1(Ros-1). EGFR mutation is the most common target of non-small cell lung cancer. Epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) is the most effective drug for the treatment of EGFR mutation advanced non-small cell lung cancer. It has been widely used in clinical treatment. However ......